Clinical Trials

20 enrolled

Breast Neoplasms

NCT06965361 2025-05-16

TIL; PD1; PDL1

Completed

54 enrolled

Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

189 enrolled

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT01815242 2025-02-27

ADAPT

336 enrolled

Breast Neoplasms

NCT02163694 2025-02-19

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

513 enrolled 16 charts

Breast Neoplasms

NCT02531932 2025-02-19

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

64 enrolled

Breast Neoplasms

NCT06618014 2025-01-16

NeoTOP

51 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02339532 2024-11-08

NeoTOP

86 enrolled

Breast Neoplasms

NCT03267316 2024-08-22

CANFOUR

BreastGastrointestinalThoracic

167 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

194 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

54 enrolled

Triple Negative Breast Neoplasms

NCT00618657 2024-02-28

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

127 enrolled 12 charts

Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT03989037 2023-12-27

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

580 enrolled

HER2-positive Early Breast Cancer

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

71 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03121352 2023-10-06

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

30 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

BreastGynecologicLymphoidOther hematologic neoplasm

41 enrolled

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

83 enrolled

Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

BreastDermatologicGastrointestinalGenitourinaryThoracic

557 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03732391 2023-01-31

Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)

22 enrolled

Breast Neoplasms

NCT03499899 2023-01-30

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

88 enrolled 35 charts

Triple Negative Breast Neoplasms

NCT02978495 2022-12-28

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

154 enrolled

BreastGynecologic

BRCA1 Hereditary Breast and Ovarian Cancer Syndrome

NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

75 enrolled

HER2 Positive Breast Cancer

NCT01795586 2022-10-31

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02419742 2022-10-12

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Phase 4 Completed

110 enrolled 10 charts

Breast Neoplasms

NCT03154749 2022-09-01

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

93 enrolled

Triple Negative Breast Neoplasms

NCT02789657 2022-05-19

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

32 enrolled 10 charts

Breast Neoplasms

NCT02435680 2021-06-21

TNBC

50 enrolled 22 charts

Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

NCT02413320 2021-05-10

NeoSTOP

101 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00723125 2021-04-29

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

60 enrolled 7 charts

Breast Neoplasms

NCT02682693 2021-02-02

GeparX

780 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02032277 2021-01-20

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

634 enrolled

Neoplasms, Triple Negative Breast Neoplasms

NCT01289353 2021-01-12

Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

92 enrolled 8 charts

Breast Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

60 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT00068341 2020-09-09

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

74 enrolled 12 charts

Breast Neoplasms

NCT00367471 2020-09-09

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

31 enrolled